Taysha Gene Therapies, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:TSHA) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 138.36 M333.33 M316.55 M343.32 M300.35 M Total liabilities 83.3 M84.6 M97.56 M96.38 M88.41 M Total equity 55.06 M248.73 M218.99 M246.94 M211.94 M Total liabilities & shareholders' equities 138.36 M333.33 M316.55 M343.32 M300.35 M Total debt 42.45 M41.05 M50.85 M50.11 M48.96 M Net debt 42.45 M41.05 M50.85 M50.11 M48.96 M

News

Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data

The Disinflation Trade Has A New Address: Genomics

Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome - Slideshow (NASDAQ:TSHA) 2026-06-23

Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript

Taysha Gene Therapies: Shortened Timeline Increases The Potential (NASDAQ:TSHA)

Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript

Taysha Gene faces earnings test as Rett trial advances

Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin

Taysha doses first patient in pivotal Rett syndrome gene therapy trial

Taysha Gene Therapies stock hits 52-week high at $5.98

Biotech Stocks: Jefferies Names its 6 Top Picks for 2026

Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock